Brief: Deutsche Biotech Innovativ Positive Results Of Phase II Study Adrenomed Adrenoss-2
16/09/2020 05:42
Sept 16 (Reuters) - DEUTSCHE BIOTECH INNOVATIV AG DBIG.DE :
* POSITIVE RESULTS OF PHASE II STUDY ADRENOMED ADRENOSS-2
INVESTIGATING ADRECIZUMAB (HAM8101) IN SEPTIC SHOCK
* ADRENOMED AG, N WHICH DEUTSCHE BIOTECH INNOVATIV AG HOLDS
A
12.8% STAKE, ANNOUNCED RESULTS OF 301-PATIENT, MULTICENTER,
DOUBLE-BLIND PHASE II ADRENOSS 2 TRIAL OF ANTIBODY ADRECIZUMAB
IN SEPTIC SHOCK
* ADRECIZUMAB RAPIDLY INCREASED PLASMA LEVELS OF BIOACTIVE
ADRENOMEDULLIN, A KEY HORMONE THAT RESTORES VASCULAR
INTEGRITY AND ENDOTHELIAL FUNCTION
Source text for Eikon: ID:nEQ8Fp8sya
Further company coverage: DBIG.DE
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;;))
Recent news on Deutsche Biotech Innovativ AG
See all newsBrief: Deutsche Biotech Innovativ Positive Results Of Phase II Study Adrenomed Adrenoss-2
Brief: Deutsche Biotech Innovativ Says Adrenomed's Antibody Adrecizumab From Shows Positive Effect In COVID-19 Patients
Brief: Deutsche Biotech Innovativ Signs Convertible Loan Agreement With SphingoTec
Brief: Deutsche Biotech Innovativ: Three Main Shareholders Divest Up To 15% Of Shares
Brief: Deutsche Biotech Innovativ Appoints Ralf M. Jakobs As New CFO